Theratechnologies to unveil promising long-term efficacy for sudocetaxel zendusortide in solid tumors at ASCO 2024
Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX), a biopharmaceutical leader focused on innovative therapy developments, has revealed Phase 1 clinical data suggesting long-term efficacy and a manageable safety profile for its novel peptide drug conjugate (PDC), sudocetaxel zendusortide (TH1902). The findings will be shared during a poster session at the 2024 American Society of Clinical Oncology […]